Novavax Inc. shares plunged as much as 26% after US Health and Human Services Secretary Robert F. Kennedy Jr. raised doubts ...

Health secretary Robert F. Kennedy Jr. this week is sowing doubt about the safety and efficacy of some vaccines — beyond the ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...

Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. HealthDay News — The US Food and Drug Administration (FDA) has delayed the full ...